ALEXANDRA is a clinical trial partnership between Roche, the Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet (IJB) and Frontier Science.

This is a phase 3, multicentre, randomised, open-label study comparing atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple negative breast cancer (TNBC).

The trial is ongoing with Frontier Science (Scotland) Ltd performing the role of statistical analysis and reporting. The statistical team in the Frontier Science Foundation office in Madison, WI is a separate firewalled statistical unit providing statistical analysis for the study’s Data Monitoring Committee.

OTHER PROJECTS

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

EPoS

EPoS

The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...

NordICC

NordICC

Colorectal cancer (CRC) is major burden in western countries which develops over a long time-interval from precursor lesions which exist in the colon. Colonoscopy can detect and remove the precursor lesions and may therefore be an effective intervention for the...

WORK WITH US

Frontier Science Scotland provides adaptable solutions across data management and biostatistics for clinical trials. To find out more, get in touch.

data management

biostatistics

quality